How Long Do Allergy Shot Benefits Last After You Stop Treatment?

Studies consistently show allergy shot benefits persist for at least 3 years after completing a full treatment course, with many patients maintaining significant improvement for 7 years or more. The landmark evidence comes from Durham et al. (NEJM 1999), which showed grass-pollen SCIT produced benefits lasting 3+ years post-discontinuation. A 2012 JACI follow-up confirmed continued benefit in most subjects at 7 years. Eng et al. (Allergy 2006) documented sustained benefit 12 years post-treatment in a small but well-studied cohort. Durability varies by allergen: venom immunotherapy is near-permanent, dust mite benefits persist up to 7 years, and pollen benefits are somewhat more variable.

Allergy shot effectiveness can gradually attenuate over years in some patients, though many maintain meaningful benefit for a decade or more. The immune changes underlying SCIT — IgG4 blocking antibody production and regulatory T-cell tolerance — do not vanish immediately after treatment ends. IgG4 levels decline slowly post-treatment but remain above pre-treatment baseline for 2-3 years (Shamji and Durham, JACI 2017). Regulatory T-cell populations established during treatment persist even as circulating antibody levels decline, providing a cellular immune memory that outlasts the antibody response. Gradual attenuation tends to occur over 5-15 years rather than abruptly, and many patients experience partial rather than complete relapse.

Relapse rates after stopping allergy shots are approximately 25% within 3 years and 30-50% by 7-10 years, though these figures vary substantially by allergen type, treatment duration, and individual factors (Eng et al., Allergy 2006). Patients who completed at least 3-5 years of maintenance have significantly better durability than those who stopped earlier. Allergen matters greatly: venom immunotherapy has a relapse rate below 10% even a decade after stopping (Golden et al., JACI 2017), while pollen allergen benefits may wane more noticeably over 5-7 years. It is important to note that relapse means return of some symptoms, not a complete immune reset — most patients retain at least partial tolerance even if full symptoms eventually return.

Current evidence and clinical guidelines favor 3-5 years of maintenance, with longer courses associated with better post-treatment durability. The AAAAI/ACAAI Practice Parameter recommends a minimum of 3 years at maintenance before considering discontinuation, with 3-5 years as the optimal window. Limited retrospective data (Naclerio et al., JACI 1997) suggest 5 years may provide marginally better long-term durability than 3 years, but head-to-head prospective data are lacking. The minimum of 3 years appears necessary to establish the regulatory T-cell memory that drives post-treatment benefit — EAACI guidelines explicitly state that 2-year courses are insufficient for sustained post-treatment effects.

Yes — retreatment after relapse is generally effective and is typically faster than the original course. The AAAAI/ACAAI Practice Parameter notes that retreatment usually requires a shorter build-up phase because residual immune memory means the immune system responds more quickly than at initial treatment. Patients who relapsed after a first course are not starting from immune scratch; Treg populations and IgG4-producing B cell memory established during the original course provide a foundation that accelerates re-establishment of tolerance. There is no documented upper limit on SCIT retreatment courses in healthy patients, though allergists will assess whether the indication remains appropriate.

Allergen-specific IgG4 blocking antibodies decline gradually after stopping allergy shots, but remain elevated above pre-treatment baseline levels for approximately 2-3 years post-discontinuation. Shamji and Durham (JACI 2017) report that IgG4 has a circulating half-life of approximately 21 days, meaning levels fall steadily after the last maintenance injection. However, IgG4-producing regulatory B cells (Bregs) persist in lymphoid tissue and can re-expand more rapidly than naive B cells upon allergen re-exposure. This cellular memory explains why clinical benefit can persist even as circulating antibody levels decline — the immune system retains an educated 'tolerance memory' that is more durable than the antibody marker alone.